TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01009866

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MR1-1
Description: Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
Study: NCT01093066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimal TURB
Description: The TURB will always try to be optically complete.
Study: NCT00249613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women-Only
Description: Gender-responsive treatment for women only
Study: NCT02345330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tavokinogene Telseplasmid (tavo)
Description: Patients received intratumoral injection(s) of tavo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical System (OMS)
Description: Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
Study: NCT04635813

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy

Intervention type: PROCEDURE
Intervention: Thyroidectomy
Description: Thyroidectomy
Study: NCT04953624

Intervention type: DIAGNOSTIC_TEST
Intervention: Appetite rating scale CNAQ
Description: Chinese version of Appetite rating scale CNAQ

Intervention type: DIAGNOSTIC_TEST
Intervention: Appetite rating scale CNAQ
Description: Chinese version of Appetite rating scale CNAQ
Study: NCT01985763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Genistein combined with FOLFOX or FOLFOX-Avastin
Study: NCT00683969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (CellCept)
Description: 1g bid for 36 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po bid for 36 weeks
Study: NCT04073758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing effects of remifentanil versus dexmedetomidine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: Comparing effects of remifentanil versus dexmedetomidine
Study: NCT02629341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Functional yogurt powder
Description: Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control yogurt powder
Description: Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
Study: NCT02436759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 Ophthalmic Solution 0.1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVL-1201 Vehicle Placebo
Description: RVL-1201 Vehicle Placebo
Study: NCT03812692

Intervention type: DEVICE
Intervention: MATRx plus
Description: The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
Study: NCT03171454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Intrauterine Balloon therapy
Description: D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate Intrauterine Balloon therapy
Description: At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
Study: NCT03849404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
Study: NCT02109146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Transcatheter Arterial Chemoembolization
Description: Participants enrolled in the adjuvant TACE group received one to two cycles of TACE with an interval of 4\~6 weeks, and the first TACE was given within 1 week after randomization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Participants enrolled in the observation group were subjected to active surveillance without any adjuvant treatment.
Study: NCT00708539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: 90 mg, vaginal, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
Study: NCT01297205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells
Description: Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
Study: NCT00295932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03264287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 times per week therapeutic frequency
Description: Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 time per week therapeutic frequency
Description: Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
Study: NCT00491387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate
Description: Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
Study: NCT01571258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
Study: NCT02621242

Intervention type: PROCEDURE
Intervention: Upper endoscopy
Description: Upper endoscopy with biopsies

Intervention type: PROCEDURE
Intervention: Anoscopy
Description: Anoscopy with biopsies

Intervention type: DRUG
Intervention: Truvada
Description: Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
Study: NCT01225575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co.don chondrosphere®
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co.don chondrosphere®
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co.don chondrosphere®
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect
Study: NCT00159250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 (PMO)
Description: morpholino antisense oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVI-4658 (PMO)
Description: morpholino antisense oligonucleotide
Study: NCT05337215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kangaroo father care
Description: The effect of postpartum kangaroo father care on paternal attachment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kangaroo father care
Description: The effect of postpartum kangaroo father care on paternal attachment
Study: NCT01845337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT01458782

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of cartilage defects in the knee
Description: Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of cartilage defects in the knee
Description: Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
Study: NCT06509269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoral scanning
Description: Intraoral Scanning of edentulous Jaw
Study: NCT02914210

Intervention type: DEVICE
Group type: OTHER
Intervention: Virtual physical therapy rehabilitation program
Description: Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
Study: NCT06509269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Desktop scanning
Description: Desktop scanning of definitive impression
Study: NCT03302988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everted closure
Description: Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar closure
Description: The planar side will be closed with traditional buried simple closure and running cuticular sutures
Study: NCT00654407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT02914210

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: Traditional physical therapy delivered in clinic or via home-health visits
Study: NCT02224157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 'as needed' + budesonide placebo bid
Description: Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
Study: NCT02947880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
Study: NCT02224157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonode bid + terbutaline 'as needed'
Description: Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
Study: NCT03630380

Intervention type: OTHER
Intervention: Clinical History
Description: We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).

Intervention type: OTHER
Intervention: Physical Exam Findings
Description: We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.

Intervention type: OTHER
Intervention: Laboratory Findings
Description: We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.

Intervention type: OTHER
Intervention: Lung Ultrasound
Description: We will perform lung ultrasound on all patients.
Study: NCT02790645

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2a. Telemedicine program
Description: CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1a. Control
Description: Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1b.Telemedicine program
Description: After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).

Intervention type: OTHER
Group type: OTHER
Intervention: Group 2b. Control
Description: After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
Study: NCT02151994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT01964547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
Study: NCT04161716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS recording
Description: Patient has a NIRS module during their urodynamic exam.
Study: NCT02826954

Intervention type: OTHER
Intervention: Upper airway assessment, including nasal biopsy

Intervention type: OTHER
Intervention: Upper airway assessment, including nasal biopsy
Study: NCT03266419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep NMB using rocuronium
Description: * Drug: rocuronium~* Bolus dose: 0.7 mg/kg~* Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate NMB using rocuronium
Description: * Drug: rocuronium~* Bolus dose: none~* Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation.
Study: NCT00980616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine, physical serum and adrenalin
Description: A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
Study: NCT03120936

Intervention type: DRUG
Group type: OTHER
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: Open-label emtricitabine 200mg/tenofovir 300mg

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PrEP support
Description: HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
Study: NCT02674399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JointStem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One
Study: NCT04373291

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark
Description: Participants randomized to receive BCG will receive one 0.1 ml dose of Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) by intradermal injection in the left deltoid region.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.
Study: NCT05435105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Distraction method

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local cold-vibration
Description: Distraction method
Study: NCT00346918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Standard plus Sirolimus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard
Study: NCT01198132

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
Study: NCT01992276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR8020
Description: 30 mg/kg administered as a single 2-hour intravenous infusion on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CR6261
Description: 30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
Study: NCT00654407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Study: NCT02344680

Intervention type: DRUG
Intervention: Anti-HIV Agents
Study: NCT01992276

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a single 2-hour intravenous infusion on Day 1
Study: NCT02590770

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attention modification
Description: participants will receive gaze-continent feedback according to their viewing patterns

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive non-gaze-continent feedback unrelated to their viewing patterns
Study: NCT02128893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study: NCT03673150

Intervention type: OTHER
Intervention: non intervention
Description: Observational study / non intervention

Intervention type: OTHER
Intervention: non intervention
Description: Observational study / non intervention
Study: NCT03863964

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: 13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: 13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood test
Description: 13 blood samples will be drawn: at 3 min, 7 min, 15 min, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, and 5h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
Study: NCT02128893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: oral